RhumbLine Advisers
MAZE

RhumbLine Advisers’s Maze Therapeutics MAZE Stock Holding History

RhumbLine Advisers’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
42,873
+11,360
+36% +$298K ﹤0.01% 2170
2026
Q1 		$941K Buy
31,513
+7,782
+33% +$343K ﹤0.01% 2225
2025
Q4 		$983K Buy
23,731
+2,761
+13% +$94.9K ﹤0.01% 2232
2025
Q3 		$544K Buy
20,970
+13,256
+172% +$224K ﹤0.01% 2643
2025
Q2 		$94.6K Buy
7,714
+479
+7% +$4.98K ﹤0.01% 3548
2025
Q1 		$79.7K Buy
+7,235
New +$87.1K ﹤0.01% 3461

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

RhumbLine Advisers's MAZE Position: Q2 2026 in Review

RhumbLine Advisers increased its Maze Therapeutics (MAZE) stake by 36% in Q2 2026, buying an estimated $298K and bringing the position to 42,873 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

RhumbLine Advisers first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • RhumbLine Advisers held 42,873 shares of Maze Therapeutics worth $1.28M as of Q2 2026.
  • RhumbLine Advisers bought 11,360 Maze Therapeutics shares in Q2 2026, an estimated $298K.
  • Maze Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2170 holding.
  • RhumbLine Advisers first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.